Search Within

Geoffrey Yuyat Ku

  1. "Smita Joshi"
Formats
  1. Meeting Abstract (3)
  2. Journal Article (2)
Groups
  1. Department of Medicine (5)
  2. Department of Pathology and Laboratory Medicine (5)
  3. Gastrointestinal Oncology Service (5)
  4. Hematologic Malignancies, Division of (5)
  5. Solid Tumor Oncology Division (5)
  6. Survivorship Research (5)

More Groups

People
  1. David Ilson (5)
  2. Laura Tang (5)
  3. Smita Joshi (5)
  4. Steven Maron (5)
  5. Yelena Janjigian (5)
  6. Daniela Molena (3)

More People

Years
  1. 2024 (2)
  2. 2023 (1)
  3. 2022 (1)
  4. 2021 (1)
Publications
  1. Journal of Clinical Oncology (2)
  2. Annals of Oncology (1)
  3. JNCI: Journal of the National Cancer Institute (1)
  4. Lancet Oncology (1)
Publishers
  1. American Society of Clinical Oncology (2)
  2. Oxford University Press (2)
  3. Elsevier Science, Inc. (1)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1b/II study of durvalumab (D) and tremelimumab (T) plus PET-adjudicated chemoradiation (CRT) in patients (Pts) with esophageal adenocarcinoma
    Meeting Abstract

    Ku, G. Y.; Wu, A. J. C.; Trivedi, N.; Maron, S. B.; Joshi, S. S.; Ilson, D. H.; Janjigian, Y. Y.; Shcherba, M.; Li, J.; Tang, L. H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer
    Journal Article

    Lumish, M. A.; Walch, H.; Maron, S. B.; Chatila, W.; Kemel, Y.; Maio, A.; Ku, G. Y.; Ilson, D. H.; Won, E.; Li, J.; more...
    JNCI: Journal of the National Cancer Institute (2024)

    Fulltext@MSK | Save
  • First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: A single-arm, single-centre, phase 2 trial
    Journal Article

    Cytryn, S. L.; Moy, R. H.; Cowzer, D.; Shah, R. H.; Chou, J. F.; Joshi, S. S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Regorafenib (REGO) with nivolumab (NIVO) and FOLFOX in HER2 negative esophagogastric cancer (EGC)
    Meeting Abstract

    Cytryn, S.; Joshi, S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; Rao, D.; Goldberg, Z.; Sugarman, R.; Antoine, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Clinical and molecular characteristics of early-onset versus average-onset esophagogastric cancer
    Meeting Abstract

    Lumish, M. A.; Sabwa, S.; Maron, S. B.; Ku, G. Y.; Ilson, D. H.; Won, E.; Li, J.; Joshi, S. S.; Gu, P.; Strong, V. E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save